Published in Bioorg Med Chem Lett on November 22, 2009
New developments in the management of hepatitis C virus infection: focus on boceprevir. Biologics (2012) 0.75
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye (Lond) (2009) 1.58
Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res (2007) 1.55
Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem (2005) 1.54
Inhibition of insulin degrading enzyme by racecadotril in the brain of Wistar rats. Horm Metab Res (2011) 1.40
Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res (2008) 1.14
Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res (2009) 1.07
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology (2013) 1.02
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J Med Chem (2006) 0.99
Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol (2009) 0.98
Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China. AIDS Res Hum Retroviruses (2008) 0.98
Propofol-related green urine. Kidney Int (2008) 0.98
Differential susceptibility to axonopathy in necrotic and non-necrotic perinatal white matter injury. Stroke (2011) 0.97
Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry (2006) 0.94
Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos (2002) 0.94
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol (2014) 0.93
Landing of size-selected Agn+ clusters on single crystal TiO2 (110)-(1x1) surfaces at room temperature. J Chem Phys (2005) 0.93
Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability. Drug Metab Dispos (2004) 0.93
Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J Biomol Screen (2007) 0.90
Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability. Protein Eng Des Sel (2008) 0.90
Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods (2008) 0.90
Evaluation of in vitro PXR-based assays and in silico modeling approaches for understanding the binding of a structurally diverse set of drugs to PXR. Biochem Pharmacol (2010) 0.88
Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase. Bioorg Med Chem Lett (2009) 0.87
Effects of PEEP levels following repeated recruitment maneuvers on ventilator-induced lung injury. Acta Anaesthesiol Scand (2008) 0.87
Potent inhibitors of HCV-NS3 protease derived from boronic acids. Bioorg Med Chem Lett (2008) 0.86
Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]. Bioorg Med Chem Lett (2005) 0.86
Identifying and quantifying secondhand smoke in source and receptor rooms: logistic regression and chemical mass balance approaches. Indoor Air (2013) 0.85
Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence. Vaccine (2005) 0.85
Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein. Antimicrob Agents Chemother (2013) 0.85
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Int (2014) 0.85
Aminothiazole inhibitors of HCV RNA polymerase. Bioorg Med Chem Lett (2005) 0.84
In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. J Antimicrob Chemother (2006) 0.84
Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochem Pharmacol (2007) 0.84
Controlled experiments measuring personal exposure to PM2.5 in close proximity to cigarette smoking. Indoor Air (2013) 0.84
Application of the lambda-dynamics method to evaluate the relative binding free energies of inhibitors to HCV protease. J Med Chem (2003) 0.84
Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding. Bioorg Med Chem Lett (2004) 0.84
Pharmacological activation of peroxisome proliferator-activated receptor δ improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice. Horm Metab Res (2011) 0.83
Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006. Virol Sin (2011) 0.83
Increased risk of pulmonary tuberculosis in patients with previous non-tuberculous mycobacterial disease. Int J Tuberc Lung Dis (2013) 0.83
Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles. J Med Chem (2009) 0.83
Characterisation and molecular epidemiology of extended-spectrum beta-lactamase-producing Enterobacter cloacae isolated from a district teaching hospital in Taiwan. Clin Microbiol Infect (2006) 0.83
Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile. J Med Chem (2009) 0.82
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles. J Med Chem (2010) 0.82
Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem (2006) 0.82
A conservative domain shared by HIV gp120 and EIAV gp90: implications for HIV vaccine design. AIDS Res Hum Retroviruses (2005) 0.82
A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors. J Med Chem (2012) 0.82
Novel dipeptide macrocycles from 4-oxo, -thio, and -amino-substituted proline derivatives. J Org Chem (2002) 0.81
Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem (2009) 0.81
A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral Res (2009) 0.81
Insights from a three-dimensional model into ligand binding to constitutive active receptor. Drug Metab Dispos (2002) 0.80
Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease. J Med Chem (2009) 0.80
Application of ring-closing metathesis for the synthesis of macrocyclic peptidomimetics as inhibitors of HCV NS3 protease. Org Lett (2007) 0.80
The Case. Generalized petechiae and acute renal failure: bilateral renal cortical necrosis in meningococcemia. Kidney Int (2008) 0.80
Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase. J Med Chem (2012) 0.80
P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease. Bioorg Med Chem Lett (2006) 0.80
Plasma glucose-lowering action of allantoin is induced by activation of imidazoline I-2 receptors in streptozotocin-induced diabetic rats. Horm Metab Res (2011) 0.79
Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease. Bioorg Med Chem Lett (2005) 0.79
Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. Curr Drug Metab (2009) 0.79
Oxidation of nanoscale Au-In alloy particles as a possible route toward stable Au-based catalysts. Proc Natl Acad Sci U S A (2013) 0.78
Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem (2006) 0.78
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor. Bioorg Med Chem Lett (2010) 0.78
Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies. Bioorg Med Chem (2009) 0.78
I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2-carboxylic acids with C3-heterocycles. Bioorg Med Chem Lett (2011) 0.77